Mission

SPV Therapeutics is advancing next-generation cyclin-dependent kinase (CDK)–based therapies designed to restore control of the cell cycle and transcriptional dysregulation that drive cancer progression. While the CDK family represents a clinically validated foundation in oncology, many cancers evade the therapeutic reach of first-generation CDK4/6 inhibitors through intrinsic or acquired resistance.

A growing body of biological evidence underscores the roles of additional CDK family members—such as CDK2 and CDK9—in sustaining proliferation, survival, and oncogenic transcriptional programs in resistant disease states. By integrating deep CDK biology, precision medicinal chemistry, and enantiopure small-molecule design, SPV’s mission and vision are aligned to deliver durable, clinically meaningful cancer control through balanced, multi-node CDK inhibition grounded in cancer-relevant biology, rather than relying on single-node pathway suppression. SPV is developing differentiated therapies for patients with advanced, treatment-resistant, and hard-to-treat cancers. 

SPV’s vision is to deliver durable, clinically meaningful cancer control through balanced, multi-node CDK inhibition aligned with cancer-relevant biology, rather than reliance on single-node pathway suppression.